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Abstract 
 
Background. Dietary carbohydrates, glycemic load and glycemic index have been 
hypothesized to influence pancreatic cancer risk, but epidemiological studies have 
been inconsistent. We conducted a systematic review and meta-analysis of 
prospective studies to clarify these results. 
 
Methods. PubMed and several other databases were searched for prospective 
studies of intake of carbohydrates, glycemic index and glycemic load and pancreatic 
cancer up to September 2011. Summary relative risks were estimated using a 
random effects model. 
 
Results. Ten cohort studies (13 publications) were included in the meta-analysis. 
The summary relative risk (RR) per 10 glycemic index units was 1.02 [95% 
confidence interval (CI): 0.93–1.12, I2 = 0%], per 50 glycemic load units was 1.03 
(95% CI: 0.93–1.14, I2 = 10%), per 100 g/day of total carbohydrates was 0.97 (95% 
CI: 0.81–1.16, I2 = 35%), and per 25 g/day of sucrose intake was 1.05 (95% CI: 
0.85–1.23, I2 = 53%). A positive association was observed with fructose intake, 
summary RR = 1.22 (95% CI: 1.08–1.37, I2 = 0%) per 25 g/day. 
 
Conclusions. This meta-analysis does not support an association between diets high 
in glycemic index, glycemic load, total carbohydrates or sucrose and pancreatic 
cancer risk. The finding of an increased risk with fructose intake warrants further 
investigation in studies with better adjustment for confounding and in non-American 
populations. 
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Introduction 
 
Pancreatic cancer is the ninth most common cause of cancer with 277 000 new 
cases diagnosed in 2008 worldwide, accounting for ∼2.2% of all cancer cases [1]. 
The survival of pancreatic cancer patients is very poor and 5-year survival rates are 
2%–8% [2]. Currently, there are no established methods for screening or early 
detection; thus, primary prevention by altering modifiable risk factors will probably be 
the most effective way of reducing the pancreatic cancer burden at present. 
Ecological studies have suggested that modifiable risk factors are likely to be 
important in pancreatic cancer etiology [3]. However, with the exception of tobacco 
smoking, which explains ∼20%–25% of pancreatic cancer cases [4, 5], and diabetes 
[relative risk (RR) = 1.8] [6] and body fatness (RR = 1.10 per 5 kg/m2) [7], relatively 
few modifiable risk factors have been firmly established. Dietary factors have been 
hypothesized to be involved in the etiology of pancreatic cancer, but to date no 
convincing dietary risk factors for pancreatic cancer have been established [8]. 
 
Several lines of evidence indicate that insulin resistance may play a role in the 
etiology of pancreatic cancer. Some established or possible risk factors for 
pancreatic cancer including overweight and obesity, low physical activity and type 2 
diabetes are linked to insulin resistance [6, 8, 9]. Epidemiological studies have 
reported increased pancreatic cancer risk with elevated blood glucose or C-peptide 
[10–12] and dietary carbohydrates are the main dietary component affecting an 
individual's insulin secretion and glycemic response [13]. Several studies have 
investigated the association between diets high in carbohydrates, glycemic index 
(GI) or glycemic load (GL) and pancreatic cancer risk; however, the results have 
been inconsistent [14–26]. Also, it is not known whether specific types of 
carbohydrates (e.g. fructose, glucose or sucrose) are associated with pancreatic 
cancer risk. Some experimental and epidemiological studies have suggested that 
high fructose intake may increase risk of insulin resistance, type 2 diabetes and 
obesity [27–29]; however, data regarding fructose intake and pancreatic cancer are 
inconsistent [14, 15, 17, 19–22]. Studies on sucrose intake and pancreatic cancer 
risk have also been inconsistent with inverse [25], null [14, 15, 17, 19, 20, 22, 23] 
and positive [21] associations reported. To clarify the association between intake of 
carbohydrates, GI, GL and pancreatic cancer risk, we conducted a systematic review 
and dose–response meta-analysis of prospective studies. 
 
 
 
  
Methods 
 
Data sources and searches 
The literature search and data extraction up to December 2005 were conducted by 
several reviewers at University of Leeds. Initially, several databases were searched 
including Pubmed, Embase, CAB Abstracts, ISI Web of Science, BIOSIS, LILACS, 
Cochrane Library, CINAHL, AMED, National Research Register and In Process . 
Because all the relevant studies were identified through searches in PubMed, a 
change in the protocol was made and only PubMed was used for the updated 
searches from January 2006 to September 2011. We followed a predefined protocol 
for the review 
(http://www.dietandcancerreport.org/cancer_resource_center/downloads/SLR_Manu
al.pdf), which includes details of the search terms. Standard criteria for conducting 
and reporting meta-analyses were followed [30]. We also searched the reference 
lists of all the studies that were included in our analysis as well as those listed in the 
published systematic reviews and meta-analyses [31, 32]. 
 
Study selection 
To be included, the study had to have a prospective cohort, case-cohort or nested 
case-control study design and to investigate the association between dietary 
carbohydrates (excluding fiber), GI or GL and pancreatic cancer risk. Estimates of 
the relative risk (hazard ratio, risk ratio) had to be available with the 95% confidence 
intervals in the publication. For the dose–response analysis, a quantitative measure 
of intake had to be provided. We identified 13 relevant publications in the search 
[14–26]. One duplicate publication [26] was excluded from the main analysis, but its 
results were included in analyses stratified by gender as the publication used for the 
main analysis [19] did not report sex-specific results and one publication was 
excluded from the dose–response analysis of sucrose and fructose intake because 
only the highest versus the lowest intake was reported [17], so no dose–response 
could be estimated for this publication. 
 
Data extraction and quality assessment 
The following data were extracted from each study: The first author's last name, 
publication year, country where the study was conducted, the study name, follow-up 
period, sample size, gender, age, number of cases, dietary assessment method 
(type, number of food items and whether it had been validated), exposure, quantity 
of intake, RRs and 95% CIs for the highest versus the lowest level of intake and 
variables adjusted for in the analysis. The search and data extraction up to 
December 2005 were conducted by JEC, DSMC, VJB and several other reviewers at 
the University of Leeds. These data were checked for accuracy by DA. The search 
and data extraction from January 2006 to September 2011 was conducted by DA 
and was checked for accuracy by TN. 
 
Data synthesis and analysis 
We used random effects models to calculate summary RRs and 95% CIs for the 
highest versus the lowest level of carbohydrate and GI/GL intake and for the dose-
response analyses [33]. The average of the natural logarithm of the RRs was 
estimated and the RR from each study was weighted by the inverse of its variance. A 
two-tailed P < 0.05 was considered statistically significant. For one study [17] that 
reported results separately for men and women, we combined the results using a 
fixed-effects model to obtain an overall combined estimate for both genders. 
 
For the dose–response analyses, we used the method by Greenland and 
Longnecker [34] to compute study-specific slopes (linear trends) and 95% CIs from 
the natural logs of the RRs and CIs across categories of carbohydrate and GI/GL 
intake. The method requires that the distribution of cases and person-years or 
noncases and the RRs with the variance estimates for at least three quantitative 
exposure categories are known. We estimated the distribution of cases or person-
years in studies that did not report these, but reported the total number of 
cases/person-years, for example, the total number of person-years was divided by 5 
when data were analyzed by quintiles in order to derive the number of person-years 
in each quintile. The median or mean level of intake in each category of intake was 
assigned to the corresponding relative risk for each study. We estimated the 
midpoint in each category by calculating the average of the lower and upper bound 
for studies that reported intakes by ranges. When the highest or lowest category was 
open ended, we assumed the open-ended interval length to be the same as the 
adjacent interval. If the intakes were reported in densities (e.g. gram per 1000 kcal), 
we recalculated the reported intakes to absolute intakes using the mean or median 
energy intake [19, 21, 22]. The dose–response results in the forest plots are 
presented for a 10- and 50-unit increment per day for GI and GL, respectively, and 
for a 100 g/day increment for total carbohydrates and 25 g/day increment for 
sucrose/fructose intake (the approximate mean difference between the highest and 
lowest intake across studies). We examined a potential nonlinear dose–response 
relationship by using fractional polynomial models [35]. The best fitting second-order 
fractional polynomial regression model was determined, defined as the one with the 
lowest deviance. A likelihood ratio test was used to assess the difference between 
the nonlinear and linear models to test for nonlinearity [36]. 
 
Heterogeneity between studies was assessed by the Q test and I2 (a measure of the 
proportion of total variation in study estimates that is due to heterogeneity) [37]. 
Subgroup and meta-regression analyses by sex, duration of follow-up, number of 
cases, geographic location and adjustment for potential confounding factors such as 
body mass index (BMI), smoking, alcohol, physical activity, intake of fruit and 
vegetables, energy and red and processed meat were conducted to investigate 
potential sources of heterogeneity. Small study effects, such as publication bias, was 
assessed by inspection of the funnel plots and with Egger's test [38] and with Begg’s 
test [39], and the results were considered to indicate small study effects when P < 
0.10. We conducted sensitivity analyses excluding one study at a time to clarify 
whether the results were simply due to one large study or a study with an extreme 
result. Results from these sensitivity analyses are reported for the two studies that 
had the most positive and negative influence on the summary estimate. 
 
 
Results 
 
We identified 10 cohort studies (13 publications) [14–26], one of which was a case-
cohort study [18], that were included in the analysis of carbohydrate, GI and GL 
intake and pancreatic cancer risk [Table 1, supplementary Figure S1 (available at 
Annals of Oncology online)]. One of these publications was only included in 
subgroup analyses by sex [26] as it was superseded by another publication from the 
same study [19]. Eight studies were from North America and two were from Europe. 
 
  
Table 1. 
Prospective cohort studies of intake of carbohydrates, glycemic index and glycemic load and pancreatic cancer risk 
 
Author, year, 
country Study name 
Follow-up 
period 
Study size, gender, 
age, number of 
cases 
Dietary 
assessment Exposure Quantity RR (95% CI) 
Adjustment for 
confounders 
Simon et al., 
2010, USA [20] 
Women's Health 
Initiative 
1993/1998–, 8 
years follow-up 
139 503 
postmenopausal 
women, age 50–79 
years: 287 cases 
Validated FFQ, 
122 food items 
Glycemic load 
150 versus 105 
units/day 0.80 (0.55–1.15) 
Age, race, income, BMI, 
physical activity, DM, 
alcohol use, smoking status, 
energy intake 
Glycemic index 
56 versus 48 
units/day 1.13 (0.78–1.63) 
Dietary total 
carbohydrates 
285 versus 203 
g/day 0.80 (0.56–1.15) 
Dietary sucrose 
60 versus 32 
g/day 1.30 (0.89–1.89) 
Dietary fructose 
33 versus 13 
g/day 0.79 (0.54–1.17) 
Meinhold et al., 
2010, USA [21] 
Prostate, Lung, 
Colorectal and 
Ovarian Cancer 
Screening Trial 
1998–2006, 
6.5 years 
follow-up 
109 175 men and 
women, age 55–74 
years: 266 cases 
Validated FFQ, 
124 food items 
Glycemic load 
≥73.57 versus 
≤54.28 g/1000 
kcal/day 1.41 (0.97–2.07) 
Age, sex, total energy, BMI, 
cigarette smoking status 
Glycemic index 
≥56.17 versus 
≤50.89 units/day 1.00 (0.69–1.47) 
Available 
carbohydrates 
≥137.00 versus 
≤102.02 g/1000 
kcal/day 1.56 (1.06–2.30) 
Starch 
≥56.27 versus 
≤38.68 g/1000 
kcal/day 1.12 (0.76–1.65) 
Sucrose 
≥29.71 versus 
≤17.04 g/1000 
kcal/day 1.55 (1.06–2.27) 
Fructose 
≥17.48 versus 
≤7.59 g/1000 
kcal/day 1.20 (0.83–1.75) 
Jiao et al., 
2009, USA [19] 
NIH-AARP Diet 
and Health Study 
1995/1996–
2003, 7.2 
years follow-up 
482 362 men and 
women, age 50–71 
years: 1151 cases 
Validated FFQ, 
124 food items 
Glycemic index 
≥52.6 versus 
24.5–46.2 
units/day 1.09 (0.90–1.32) 
Age, sex, total energy 
intake, smoking, alcohol, 
SFA, red meat, BMI 
Total 
carbohydrate 
≥151.5 versus 
9.0 1.12 (0.84–1.50) 
Available 
carbohydrate 
≥138.9 versus 
8.7 1.11 (0.84–1.46) 
Glycemic load ≥74.9 versus 4.0 0.95 (0.74–1.22) 
Author, year, 
country Study name 
Follow-up 
period 
Study size, gender, 
age, number of 
cases 
Dietary 
assessment Exposure Quantity RR (95% CI) 
Adjustment for 
confounders 
Starch 
≥59.0 versus 
0.55 0.95 (0.78–1.16) 
Sucrose 
≥30.0 versus 
0.45 0.95 (0.78–1.16) 
Lactose ≥12.2 versus 0 0.89 (0.73–1.09) 
Maltose ≥2.34 versus 0 1.07 (0.88–1.29) 
Free fructose 
≥18.4 versus 
0.10 1.29 (1.04–1.59) 
Free glucose 
≥17.4 versus 
0.45 1.35 (1.10–1.67) 
Galactose ≥0.18 versus 0 0.91 (0.75–1.11) 
Total sugar 
≥75.8 versus 
2.16 1.10 (0.88–1.38) 
George et al., 
2009, USA [26] 
NIH-AARP Diet 
and Health Study 
1995/1996–
2003, 7.2 
years follow-up 
262 642 men and 
183–535 women, age 
50–71 years: 601/348 
cases 
Validated FFQ, 
124 food items 
Glycemic index, 
men 
≥57.02 versus 
≤51.26 units/day 1.19 (0.92–1.55) 
Age, race/ethnicity, 
education, marital status, 
BMI, family history of any 
cancer, physical activity, 
smoking, alcohol, total 
energy, menopausal 
hormone therapy (women) 
     
Glycemic load 
≥164.44 versus 
≤83.20 units/day 0.67 (0.42–1.08) 
     
Glycemic index, 
women 
≥56.56 versus 
≤50.43 units/day 1.00 (0.71–1.40) 
     
Glycemic load 
≥135.31 versus 
≤66.91 units/day 0.49 (0.26–0.94) 
Meinhold et al., 
2009, Finland 
[25] 
Alpha-Tocopherol 
Beta-Carotene 
Cancer Prevention 
Study 
1985/1988–
2004, 16.1 
years follow-up 
27 035 smoking men, 
age 50–69 years: 305 
cases 
Validated FFQ, 
276 food items 
Available 
carbohydrates 
312 versus 221 
g/day 0.65 (0.46–0.93) Age, BMI, cigarettes per 
day, years of smoking, total 
energy, DM Sucrose 
84.3 versus 24.9 
g/day 0.68 (0.47–0.98) 
Heinen et al., 
2008, The 
Netherlands [18] 
Netherlands 
Cohort Study 
1986–1999, 
13.3 years 
follow-up 
3980 men and women, 
age 55–69 years: 408 
cases 
Validated FFQ, 
150 items 
Glycemic load 
156 versus 88 
units/day 0.85 (0.58–1.24) 
Age, sex, energy intake, 
smoking status, cigarettes 
per day, years of smoking, 
alcohol, DM, hypertension, 
BMI, vegetables, fruit, fiber 
 
Per 50 g/day 1.03 (0.77–1.39) 
Glycemic index 
64 versus 55 
units/day 0.87 (0.59–1.29) 
 
Per 5 units 0.98 (0.81–1.19) 
Total 
carbohydrate 
256 versus 155 
g/day 1.03 (0.69–1.52) 
 
Per 50 g/day 1.04 (0.85–1.27) 
Nothlings et al., 
2007, USA [22] 
Multiethnic Cohort 
Study 
1993/1996–
2002, 8 years 
follow-up 
162 150 men and 
women, age 45–75 
years: 434 cases 
Validated FFQ, 
180 food items 
Glycemic load 
≥82.3 
versus < 63.3 
g/1000 kcal/day 1.10 (0.80–1.52) 
Age, race-ethnicity, smoking 
status, pack-yrs of smoking, 
family history of pancreatic 
cancer, energy intake, red Carbohydrates ≥58.7 1.04 (0.75-1.46) 
Author, year, 
country Study name 
Follow-up 
period 
Study size, gender, 
age, number of 
cases 
Dietary 
assessment Exposure Quantity RR (95% CI) 
Adjustment for 
confounders 
versus < 46.7 
g/1000 kcal/day 
and processed meat, BMI 
Sucrose 
≥22.1 
versus < 13.7 
g/1000 kcal/day 1.23 (0.91–1.65) 
Fructose 
≥15.4 
versus < 7.3 
g/1000 kcal/day 1.35 (1.02–1.80 
Total sugar 
≥62.6 
versus < 40.0 
g/1000 kcal/day 1.28 (0.95–1.73) 
Added sugars 
≥6.5 
versus < 3.2 
g/1000 kcal/day 1.08 (0.81–1.44) 
Patel et al., 
2007, USA [17] 
Cancer Prevention 
Study 2 Nutrition 
Cohort 
1992/1997–
2001, 9 years 
follow-up 
124 907 men and 
women, age 50–74 
years: 401 cases 
Validated FFQ, 
68 food items 
Glycemic load, 
men 
>169.88 versus 
≤119.02 
units/day 1.10 (0.73–1.64) 
Age, sex, race, BMI, 
gallstones, smoking, total 
energy intake, family history 
of pancreatic cancer, 
location of weight gain, 
sedentary behavior 
Glycemic index 
>81.83 versus 
≤69.61 units/day 0.80 (0.53–1.20) 
Carbohydrate 
intake 
>218.93 versus 
≤162.56 g/day 1.28 (0.83–1.96) 
Glycemic load, 
women 
>132.37 versus 
≤95.13 units/day 0.89 (0.56–1.45) 
Glycemic index 
>79.96 versus 
≤68.42 units/day 1.11 (0.71–1.74) 
Carbohydrate 
intake 
>177.15 versus 
≤129.98 g/day 0.90 (0.56–1.45) 
Sucrose, men 
and women 
Quintile 5 versus 
1 0.84 (0.62–1.14) 
Fructose, men 
and women 
Quintile 5 versus 
1 1.00 (0.73–1.36) 
Johnson et al., 
2005, USA [16] 
Iowa Women's 
Health Study 
1986–2002, 16 
years follow-up 
33 551 women, age 
55–69 years: 181 
cases 
Validated FFQ, 
126 food items 
Glycemic index 
>89 versus < 82 
units/day 1.08 (0.74–1.58) 
Age, smoking, pack-years, 
DM, multivitamin use Glycemic load 
>188 
versus < 151 0.87 (0.56–1.34) 
Silvera et al., 
2005, Canada 
[15] 
Canadian National 
Breast Screening 
Study 
1980/1985–
2000, 16.5 
years follow-up 
49 613 women: 112 
cases 
Validated FFQ, 
86 food items 
Glycemic index 
>92 versus < 63 
units/day 1.43 (0.56–3.65) 
Age, BMI, alcohol, smoking, 
parity, energy intake, study 
center, randomization group 
Glycemic load 
>169 
versus < 125 0.80 (0.45–1.41 
Total 
carbohydrate 
>236 
versus < 152 0.63 (0.31–1.26) 
Author, year, 
country Study name 
Follow-up 
period 
Study size, gender, 
age, number of 
cases 
Dietary 
assessment Exposure Quantity RR (95% CI) 
Adjustment for 
confounders 
g/day 
Total sugar 
>96 versus < 64 
g/day 0.99 (0.59–1.66) 
Sucrose 
>34 versus < 17 
g/day 0.64 (0.35–1.17) 
Fructose 
>25 versus < 13 
g/day 1.18 (0.65–2.13) 
Stolzenberg-
Solomon 2002, 
Finland [24] 
Alpha-Tocopherol 
Beta-Carotene 
Cancer Prevention 
Study 
1985/1988–
1997, 10.2 
years follow-up 
27 111male smokers, 
age 50–69 years: 163 
cases 
Validated FFQ, 
276 food items Carbohydrate 
>330.2 versus 
≤260.7 g/day 0.62 (0.37–1.03) 
Energy, age, years of 
smoking 
Michaud et al., 
2002, USA [14] 
Nurses' Health 
Study 
1980–1998, 18 
years follow-up 
88 802 women, age 
34–59 years: 180 
cases 
Validated FFQ, 
61 food items 
Glycemic load 
167 versus 80 
g/day 1.53 (0.96–2.45) 
Age, height, BMI, pack-
years of smoking, DM, 
cholecystectomy, calorie 
intake, physical activity 
Glycemic index 81 versus 65 1.16 (0.69–1.97) 
Carbohydrates 
202 versus 110 
g/day 1.30 (0.81–2.09) 
Sucrose 
55 versus 17 
g/day 1.34 (0.82–2.17) 
Fructose 
45 versus 11 
g/day 1.57 (0.95–2.57) 
Harnack et al., 
1997, USA [23] 
Iowa Women's 
Health Study 
1986–1994, 8 
years follow-up 
33 976 women, age 
55–69 years: 66 cases 
Validated FFQ, 
126 food items 
Carbohydrate 
>238 versus 
≤178 g/day 1.22 (0.67–2.20) 
Age, smoking status, pack-
years Sucrose 
>47 versus ≤30 
g/day 0.94 (0.50–1.75) 
 
Glycemic index 
High versus low analysis 
Eight cohort studies [14–21] were included in the high versus low analysis of GI and 
pancreatic cancer risk and included 2986 cases among 1 031 893 participants. The 
summary RR for all studies was 1.04 [95% confidence interval (CI): 0.93–1.17, I2 = 
0%, Pheterogeneity = 0.92] (supplementary Figure S2a, available at Annals of Oncology 
online). 
 
Dose–response analysis 
Eight cohort studies [14–21] were included in the dose–response analysis. The 
summary RR per 10 units/day was 1.02 (95% CI: 0.93–1.12, I2 = 0%, Pheterogeneity = 
0.97) (Figure 1a) [14–21]. The summary RR ranged from 1.01 (95% CI: 0.91–1.11) 
when the Canadian National Breast Cancer Screening Study was excluded to 1.05 
(95% CI: 0.94–1.17) when the Cancer Prevention Study 2 Nutrition Cohort was 
excluded. There was no indication of small study effects with Egger’s test, P = 0.54 
or with Begg’s test, P = 0.26. There was no evidence for a nonlinear association 
between GI and pancreatic cancer risk, Pnonlinearity = 1.00 (supplementary Figure 
S3a, available at Annals of Oncology online). 
 
  
Figure 1. 
Glycemic index, glycemic load, total carbohydrates and sucrose intake and 
pancreatic cancer, dose–response analysis. 
 
 
 
 
  
 Glycemic load 
High versus low analysis 
Nine cohort studies [14–22] were included in the analysis of high versus low GL and 
pancreatic cancer risk and included a total of 3420 cases among 1 194 043 
participants. The summary RR was 1.01 (95% CI: 0.88–1.15, I2 = 19%, Pheterogeneity = 
0.27) (supplementary Figure S2b, available at Annals of Oncology online). 
 
Dose-response analysis 
Nine cohort studies [14–22] were included in the dose–response analysis. The 
summary RR per 50 units/day was 1.03 (95% CI: 0.93–1.14, I2 = 10%, Pheterogeneity = 
0.35) (Figure 1b). In a sensitivity analysis, the summary RR ranged from 1.01 (95% 
CI: 0.91–1.12) when excluding the Nurses' Health Study to 1.05 (95% CI: 0.95–1.16) 
when excluding the National Institutes of Health - American Association of Retired 
Persons (NIH-AARP) Diet and Health Study. There was no indication of small study 
effects with Egger’s test, P = 0.68, or with Begg’s test, P = 0.60. There was no 
evidence for a nonlinear association between GL and pancreatic cancer risk, 
Pnonlinearity = 0.51 (supplementary Figure S3b, available at Annals of Oncology 
online). 
 
Total carbohydrates 
High versus low analysis 
Nine cohort studies [14, 15, 17–20, 22–24] were included in the high versus low 
analysis of total carbohydrate intake and pancreatic cancer risk and included 3202 
cases among 1 112 404 participants. The summary RR was 1.00 (95% CI: 0.86–
1.15, I2 = 35%, Pheterogeneity = 0.14) (supplementary Figure S2c, available at Annals of 
Oncology online). 
 
Dose–response analysis 
Nine cohort studies [14, 15, 17–20, 22–24] were included in the dose–response 
analysis. The summary RR per 100 g/day was 0.97 (95% CI: 0.81–1.16, I2 = 35%, 
Pheterogeneity = 0.14) (Figure 1c). The summary RR ranged from 0.92 (95% CI: 0.75–
1.13) when excluding the NIH-AARP Diet and Health Study to 1.04 (95% CI: 0.90–
1.21) when excluding the Alpha-Tocopherol and Beta-Carotene Cancer Prevention 
Study. There was no evidence of small study effects with Egger’s test, P = 0.42, or 
with Begg’s test, P = 0.47. There was no evidence for a nonlinear association 
between carbohydrates and pancreatic cancer risk, Pnonlinearity = 0.32 
(supplementary Figure S3c, available at Annals of Oncology online). 
 Sucrose 
High versus low analysis 
Nine cohort studies [14, 15, 17, 19–23, 25] were included in the high versus low 
analysis of sucrose intake and pancreatic cancer and included 3202 cases among 1 
217 523 participants. The summary RR was 1.02 (95% CI: 0.85–1.23, I2 = 56%, 
Pheterogeneity = 0.02) (supplementary Figure S2d, available at Annals of Oncology 
online). 
 
Dose–response analysis 
Eight cohort studies [14, 15, 19–23, 25] were included in the dose–response 
analysis. The summary RR per 25 g/day was 1.05 (95% CI: 0.92–1.19, I2 = 53%, 
Pheterogeneity = 0.04) (Figure 1d). The summary RR ranged from 1.02 (95% CI: 0.89–
1.16) when the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial study 
was excluded to 1.10 (95% CI: 0.97–1.24) when the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study was excluded. There was no evidence of small 
study effects with Egger’s test, P = 0.71, or Begg’s test, P = 0.71. There was no 
evidence of a nonlinear association between sucrose and pancreatic cancer risk, 
Pnonlinearity = 0.14 (supplementary Figure S3d, available at Annals of Oncology 
online). 
 
Fructose 
High versus low analysis 
Seven cohort studies [14, 15, 17, 19–22] were included in the high versus low 
analysis of fructose intake and pancreatic cancer and included 2831 cases among 1 
156 512 participants. The summary RR was 1.18 (95% CI: 1.01–1.37, I2 = 25%, 
Pheterogeneity = 0.24) (supplementary Figure S4, available at Annals of Oncology 
online). 
 
Dose–response analysis 
Six cohort studies [14, 15, 19–22] were included in the dose–response analysis of 
fructose intake and pancreatic cancer risk. The summary RR for a 25 g/day 
increment was 1.22 (95% CI: 1.08–1.37, I2 = 0%, Pheterogeneity = 0.43) (Figure 2a). The 
summary RR ranged from 1.16 (95% CI: 0.99–1.36) when excluding the NIH-AARP 
Diet and Health study to 1.26 (95% CI: 1.12–1.42) when excluding the Women's 
Health Initiative. There was no evidence of small study effects with Egger’s test, P = 
0.22, although some evidence with Begg’s test, P = 0.06. When excluding one study 
[20] from the analysis, Begg’s test showed P = 0.22, but the summary RR remained 
similar, 1.26 (95% CI: 1.12–1.42). There was no evidence for a nonlinear association 
between fructose intake and pancreatic cancer, Pnonlinearity = 1.00 (Figure 2b). 
 
  
Figure 2. 
Fructose and pancreatic cancer, dose–response analysis. 
 
 
  
Other carbohydrates 
Few studies investigated the association between intake of other carbohydrates and 
pancreatic cancer risk. The summary RR for high versus low intake was 1.14 (95% 
CI: 0.96–1.35, I2 = 0%, Pheterogeneity = 0.62, n = 3) for total sugar [15, 19, 22], 1.04 
(95% CI: 0.65–1.64, I2 = 82%, Pheterogeneity = 0.004, n = 3) for available carbohydrates 
(total carbohydrates minus fiber) [19, 21, 25] and 0.98 (95% CI: 0.82–1.17, I2 = 0%, 
Pheterogeneity = 0.46, n = 2) for starch (results not shown) [19, 21]. There were not 
enough studies to conduct analyses of lactose, maltose, glucose, or galactose. 
 
Subgroup, meta-regression and sensitivity analyses 
In subgroup analyses, the results were consistent in showing no association 
between intake of GI, GL, total carbohydrates or sucrose and pancreatic cancer risk 
(supplementary Tables S1 and S2, available at Annals of Oncology online). There 
was a significant association for fructose intake in the subgroups of studies that 
adjusted for smoking [14, 15, 19–22], BMI [14, 15, 19–22], red and processed meat 
intake [19, 22] and energy intake [14, 15, 19–22], but there was no association in the 
subgroups of studies that adjusted for intake of alcohol [15, 19, 20], diabetes status 
[14, 20] or physical activity [14, 20], although the number of studies was low in some 
of these subgroups (Table 2). In meta-regression analyses, there was, however, no 
evidence of heterogeneity between the subgroups with and without adjustment for 
these factors, neither in the fructose analysis (Table 2) nor in the analysis of total 
carbohydrates, GI, GL or sucrose (supplementary Tables S1 and S2, available at 
Annals of Oncology online). Because not all studies reported on all types of 
carbohydrates, we conducted further sensitivity analyses using the same dataset to 
clarify if there was a ‘study effect’. When the analyses were restricted to the studies 
that were common for the analyses of total carbohydrates, sucrose and fructose [14, 
15, 19, 20, 22], the summary RR was 1.00 (95% CI: 0.78–1.29, I2 = 37%, Pheterogeneity 
= 0.17) for total carbohydrates, 1.08 (95% CI: 0.93–1.25, I2 = 38%, Pheterogeneity = 
0.17) for sucrose and 1.21 (95% CI: 1.05–1.40, I2 = 16%, Pheterogeneity = 0.32) for 
fructose. 
 
  
Table 2. 
Subgroup analyses of fructose intake and pancreatic cancer, dose–response 
analysis 
 
Fructose 
  
n RR (95% CI) I2 (%) Pha Phb 
All studies 6 1.22 (1.08–1.37) 0 0.43 
 Sex 
      Men 0 
   NC  Women 3 1.05 (0.73–1.49) 38.6 0.20 
Duration of follow-up 
       < 10 years follow-up 4 1.17 (0.98–1.40) 38.6 0.18 
0.89  ≥10 years follow-up 2 1.25 (0.92–1.69) 0 0.98 
Geographic location 
      Europe 0 
   NC  America 6 1.22 (1.08–1.37) 0 0.43 
Number of cases 
      Cases < 300 4 1.09 (0.87–1.36) 9.5 0.35 
0.29 
 Cases 300 to < 499 1 1.26 (0.98–1.61) 
   Cases ≥500 1 1.30 (1.09–1.54) 
  Adjustment for confounding factors 
 
 Alcohol 
Yes 3 1.08 (0.74–1.58) 57.2 0.10 
0.77 No 3 1.23 (1.03–1.46) 0 0.89 
 Smoking 
Yes 6 1.22 (1.08–1.37) 0 0.43 
NC No 0 
   
 Diabetes 
Yes 2 1.00 (0.60–1.64) 67.9 0.08 
0.31 No 4 1.26 (1.11–1.44) 0 0.93 
 Body mass index 
Yes 6 1.22 (1.08–1.37) 0 0.43 
NC No 0 
   
 Physical activity 
Yes 2 1.00 (0.60–1.64) 67.9 0.08 
0.31 No 4 1.26 (1.11–1.44) 0 0.93 
 Red, processed meat 
Yes 2 1.28 (1.11–1.48) 0 0.85 
0.28 No 4 1.09 (0.87–1.36) 9.5 0.35 
 Fruits, vegetables 
Yes 0 
   NC No 6 1.22 (1.08–1.37) 0 0.43 
 Energy intake 
Yes 6 1.22 (1.08–1.37) 0 0.43 
NC No 0 
   
 
RR, relative risk; CI, confidence interval; ‘n’, denotes the number of studies; NC, not 
calculable because no studies were present in one of the subgroups. 
aP for heterogeneity within each subgroup. 
bP for heterogeneity between subgroups with meta-regression analysis. 
 
 
  
Discussion 
 
We found no statistically significant association between intake of total 
carbohydrates, sucrose, GI or GL and pancreatic cancer risk in categorical and 
dose–response meta-analyses. However, to our knowledge, this is the first meta-
analysis to report an association between intake of fructose and increased 
pancreatic cancer risk. 
 
Our meta-analysis may have several limitations which must be taken into 
consideration. Intake of diets high in fructose, carbohydrates, GI and GL may be 
associated with other behaviors including physical activity, overweight and obesity, 
smoking and intake of alcohol and red and processed meat, which possibly could 
confound associations we observed. The results for fructose intake persisted in 
studies that adjusted for smoking [14, 15, 19–22], BMI [14, 15, 19–22], intake of red 
and processed meat [19, 22] and energy intake [14, 15, 19–22]; however, there was 
no association in the few studies that adjusted for alcohol [15, 19, 20], diabetes [14, 
20] and physical activity [14, 20]. Because of the few studies in some of these 
subgroup analyses interpretation of these analyses is difficult. There was no 
evidence of heterogeneity between these subgroups with and without adjustment for 
these potentially confounding factors. For the other exposures, the results were 
similar across subgroups and there was no evidence of heterogeneity between the 
subgroups. We found little evidence of small study effects in this analysis and in the 
one analysis where there was some indication of small study effects this was caused 
by only one study [20] and exclusion of that study did not change the results. 
 
Measurement errors in the assessment of dietary intake are known to bias effect 
estimates; however, none of the studies included in this meta-analysis made any 
corrections for measurement errors. Any measurement errors would, however, most 
likely result in bias toward the null and, thus, underestimate the association between 
fructose and carbohydrate intake and pancreatic cancer risk. Assessment of GI or 
GL may be particularly challenging because these measures are based on their 
postprandial blood glucose response and are not concentration values of nutrients in 
the foods consumed. Most dietary questionnaires have estimated usual GI or GL 
values based on a limited number of food items, which may not have been 
specifically selected and validated for dietary GI or GL. However, studies using 
similar questionnaires have been able to detect associations between GI or GL and 
risk of type 2 diabetes [40] and cardiovascular disease [41], although we cannot 
exclude the possibility that a weak association with pancreatic cancer may have 
been obscured due to measurement errors. 
 
The specific mechanism that may explain an association between fructose intake 
and pancreatic cancer remains speculative, but the metabolism of fructose differs 
from other carbohydrates such as glucose. Recently, it has been shown that the 
contribution of fructose to nucleic acid synthesis through the pentose phosphate 
pathway (catalyzed by transketolase) is greater than glucose [42]. Synthesis of 
nucleic acids and nucleotides is necessary for proliferating tissues and in particular, 
cancer cells. It has been shown that suppression of transketolase-like protein 1 
reduces cancer cell proliferation [43, 44] while activation of transketolase stimulates 
tumor growth [45]. The contribution of fructose to the generation of nucleic acids is 
further illustrated by increased production of uric acid [42], a by-product of purine 
metabolism, and increased risk of gout among high fructose consumers [46]. 
Interestingly, one study reported an elevated pancreatic cancer risk among men with 
high serum uric acid levels, although no association was observed in women [47]. In 
addition, experimental studies have shown that chronic fructose feeding in animals 
leads to insulin resistance and obesity [27]. Several [28, 48–50], but not all [51] 
epidemiological and experimental studies have reported positive associations 
between fructose intake and type 2 diabetes and obesity in humans as well, both of 
which are established risk factors for pancreatic cancer; however, all the studies 
included in the analysis of fructose and pancreatic cancer risk adjusted for BMI, 
suggesting an association independent of BMI. 
 
Our meta-analysis also has several strengths. Because we based our analyses on 
prospective studies, we have effectively avoided recall bias and reduced the 
possibility of selection bias. Our meta-analysis is consistent with two previous meta-
analyses that found no association between GI and GL and pancreatic cancer risk 
based on five to six cohort studies [31, 32]. However, with three additional studies, 
our meta-analysis included a total of ∼1–1.2 million participants, depending on the 
exposure, and ∼3000 cases. Thus, we had statistical power to detect moderate 
associations. In addition, we conducted more detailed subgroup analyses and dose–
response analyses. Our results suggest that only specific types of carbohydrates 
may increase pancreatic cancer risk. It is possible that the association may reflect 
certain foods or drinks with a high fructose content. Fructose is a monosaccharide 
found naturally in fruits and vegetables, but data regarding fruit intake and pancreatic 
cancer risk have indicated a reduced risk, although the evidence was considered 
only limited suggestive in the World Cancer Research Fund/American Institute for 
Cancer Research report from 2007, while data on vegetable intake were even more 
limited or conflicting [8]. In addition, prospective data on specific types of fruits and 
vegetables pancreatic cancer risk are sparse. Fructose has also largely replaced 
sucrose as a sweetener in soft drinks in the past 10–20 years in the United States, 
although not in Europe. The third National Health and Nutrition Examination Survey 
reported that over 10% of American’s daily calories come from fructose, of which the 
largest part came from sugar-sweetened beverages (30%), followed by grains (22%) 
and fruit or fruit juice (19%) [52]. Some studies have reported elevated risk of 
pancreatic cancer with high intake of sugar-sweetened beverages [53–55] which can 
be high in high-fructose corn syrup, although the data are not completely consistent 
[22, 56, 57]. A meta-analysis found a summary RR of 1.21 (95% CI: 0.90–1.63) for 
heavy soft drink consumers among five cohort studies [57], while a more recent 
pooled analysis of 14 cohort studies reported a nonsignificant increase in risk for 
≥250 versus 0 g/day of soft drink intake, RR = 1.19 (95% CI: 0.98–1.46), which 
reached significance on a continuous scale, RR = 1.06 (95% CI: 1.02–1.12) per 175 
g/day [58]. These estimates are of similar size as our results for fructose intake. 
Further studies of fructose intake and specific sources of fructose and pancreatic 
cancer risk are warranted since all the studies reporting on fructose intake were 
American and it is not known whether these findings apply to other populations. 
 
In conclusion, our results indicate that intake of fructose, but not total carbohydrates, 
sucrose, GI or GL, increases the risk of pancreatic cancer. Given the few established 
dietary risk factors for pancreatic cancer, further studies of fructose intake and 
pancreatic cancer risk with better adjustment for confounding factors are warranted 
to confirm or refute these findings and to clarify whether the results reflect the effect 
of specific foods or drinks. 
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